1. In silico design of a novel multi-epitope vaccine against HCV infection through immunoinformatics approaches.
- Author
-
Ahmad, Sajjad, Demneh, Fatemeh Mobini, Rehman, Bushra, Almanaa, Taghreed N., Akhtar, Nahid, Pazoki-Toroudi, Hamidreza, Shojaeian, Ali, Ghatrehsamani, Mahdi, and Sanami, Samira
- Subjects
- *
HEPATITIS C , *CHOLERA toxin , *ESCHERICHIA coli - Abstract
Infection with the hepatitis C virus (HCV) is one of the causes of liver cancer, which is the world's sixth most prevalent and third most lethal cancer. The current treatments do not prevent reinfection; because they are expensive, their usage is limited to developed nations. Therefore, a prophylactic vaccine is essential to control this virus. Hence, in this study, an immunoinformatics method was applied to design a multi-epitope vaccine against HCV. The best B- and T-cell epitopes from conserved regions of the E2 protein of seven HCV genotypes were joined with the appropriate linkers to design a multi-epitope vaccine. In addition, cholera enterotoxin subunit B (CtxB) was included as an adjuvant in the vaccine construct. This study is the first to present this epitopes-adjuvant combination. The vaccine had acceptable physicochemical characteristics. The vaccine's 3D structure was predicted and validated. The vaccine's binding stability with Toll-like receptor 2 (TLR2) and TLR4 was confirmed using molecular docking and molecular dynamics (MD) simulation. The immune simulation revealed the vaccine's efficacy by increasing the population of B and T cells in response to vaccination. In silico expression in Escherichia coli (E. coli) was also successful. • This study focused on designing a multi-epitope vaccine against HCV. • The conserved regions of the E2 protein were used to predict epitopes. • A vaccine was constructed by joining epitopes, linkers, and an adjuvant. • The vaccine was found to be antigenic, non-toxic, and non-allergenic. • The vaccine revealed a stable molecular interaction with innate immune receptors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF